Literature DB >> 21611839

UHRF1 is associated with tumor recurrence in non-muscle-invasive bladder cancer.

Guo-Liang Yang1, Lian-Hua Zhang, Juan-Jie Bo, Hai-Ge Chen, Ming Cao, Dong-Ming Liu, Yi-Ran Huang.   

Abstract

Ubiquitin-like with PHD and ring finger domains 1 (UHRF1) is a novel anti-apoptotic gene, and overexpression of UHRF1 is involved in tumorigenicity. Here, immunohistochemistry was used to detect UHRF1 expression in non-muscle-invasive bladder cancer (NMIBC), and these data were examined for correlation with clinicopathological parameters and prognosis. The UHRF1 expression rate was 49.2% in a total of 118 bladder cancer tissues, which was significantly higher than in normal tissues, and UHRF1 expression has a significantly positive correlation with tumor grade (P = 0.027) and recurrence (P = 0.013). Survival analysis showed that UHRF1 high expression patients' mean survival time (42.59 months) was significantly shorter than that (71.36 months) of UHRF1 low expression patients (P = 0.0002). Multivariate analysis showed that UHRF1 overexpression was an independent prognostic factor for tumor recurrence (P < 0.0001). So UHRF1 may be a molecular marker to predict the recurrence of NMIBC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21611839     DOI: 10.1007/s12032-011-9983-z

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  29 in total

Review 1.  Bladder. Risk and prognostic factors--a pathologist's perspective.

Authors:  V E Reuter
Journal:  Urol Clin North Am       Date:  1999-08       Impact factor: 2.241

2.  Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.

Authors:  Vasilios E Theodoropoulos; Andreas C Lazaris; Ioannis Kastriotis; Chariclia Spiliadi; George E Theodoropoulos; Vasiliki Tsoukala; Efstratios Patsouris; Frank Sofras
Journal:  BJU Int       Date:  2005-02       Impact factor: 5.588

Review 3.  Multivariate analysis of the prognostic factors of primary superficial bladder cancer.

Authors:  F Millán-Rodríguez; G Chéchile-Toniolo; J Salvador-Bayarri; J Palou; J Vicente-Rodríguez
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

4.  Cloning and mapping of Np95 gene which encodes a novel nuclear protein associated with cell proliferation.

Authors:  A Fujimori; Y Matsuda; Y Takemoto; Y Hashimoto; E Kubo; R Araki; R Fukumura; K Mita; K Tatsumi; M Muto
Journal:  Mamm Genome       Date:  1998-12       Impact factor: 2.957

5.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

6.  Structure and hemimethylated CpG binding of the SRA domain from human UHRF1.

Authors:  Chengmin Qian; Side Li; Jean Jakoncic; Lei Zeng; Martin J Walsh; Ming-Ming Zhou
Journal:  J Biol Chem       Date:  2008-10-22       Impact factor: 5.157

7.  Recognition of hemi-methylated DNA by the SRA protein UHRF1 by a base-flipping mechanism.

Authors:  Kyohei Arita; Mariko Ariyoshi; Hidehito Tochio; Yusuke Nakamura; Masahiro Shirakawa
Journal:  Nature       Date:  2008-09-03       Impact factor: 49.962

8.  The characterization of the monoclonal antibody Th-10a, specific for a nuclear protein appearing in the S phase of the cell cycle in normal thymocytes and its unregulated expression in lymphoma cell lines.

Authors:  M Muto; M Utsuyama; T Horiguchi; E Kubo; T Sado; K Hirokawa
Journal:  Cell Prolif       Date:  1995-12       Impact factor: 6.831

9.  The interaction of the SRA domain of ICBP90 with a novel domain of DNMT1 is involved in the regulation of VEGF gene expression.

Authors:  M Achour; X Jacq; P Rondé; M Alhosin; C Charlot; T Chataigneau; M Jeanblanc; M Macaluso; A Giordano; A D Hughes; V B Schini-Kerth; C Bronner
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

Review 10.  Bladder cancer.

Authors:  Donald S Kaufman; William U Shipley; Adam S Feldman
Journal:  Lancet       Date:  2009-06-10       Impact factor: 79.321

View more
  18 in total

1.  Elevated expression of UHRF1 predicts unfavorable prognosis for patients with hepatocellular carcinoma.

Authors:  Dong Liang; Huanzhou Xue; Yang Yu; Feng Lv; Wei You; Bin Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

2.  UHRF1 promotes proliferation of gastric cancer via mediating tumor suppressor gene hypermethylation.

Authors:  Lin Zhou; Yulong Shang; Zhi'an Jin; Wei Zhang; Chunlei Lv; Xiaodi Zhao; Yongqiang Liu; Naiyi Li; Jie Liang
Journal:  Cancer Biol Ther       Date:  2015-07-06       Impact factor: 4.742

3.  Overexpression of UHRF1 is significantly associated with poor prognosis in laryngeal squamous cell carcinoma.

Authors:  Jing-Ting Pi; Ye Lin; Qiu Quan; Li-Li Chen; Li-Zhu Jiang; Wang Chi; Hong-Yan Chen
Journal:  Med Oncol       Date:  2013-09-05       Impact factor: 3.064

4.  DNA damage regulates UHRF1 stability via the SCF(β-TrCP) E3 ligase.

Authors:  Hao Chen; Honghui Ma; Hiroyuki Inuzuka; Jianbo Diao; Fei Lan; Yujiang Geno Shi; Wenyi Wei; Yang Shi
Journal:  Mol Cell Biol       Date:  2013-01-07       Impact factor: 4.272

5.  Analysis of UHRF1 expression in human ovarian cancer tissues and its regulation in cancer cell growth.

Authors:  Feng Yan; Xiaoming Wang; Lijia Shao; Mengyuan Ge; Xiaoya Hu
Journal:  Tumour Biol       Date:  2015-06-13

6.  Clinicopathological analysis of UHRF1 expression in medulloblastoma tissues and its regulation on tumor cell proliferation.

Authors:  Zhen-Yu Zhang; Jia-Jun Cai; Jin Hong; Kay Ka-Wai Li; Zhou Ping; Yin Wang; Ho-Keung Ng; Yu Yao; Ying Mao
Journal:  Med Oncol       Date:  2016-07-23       Impact factor: 3.064

7.  Predictive value of Sox2 expression in transurethral resection specimens in patients with T1 bladder cancer.

Authors:  Jun Ruan; Bingbing Wei; Zhuoqun Xu; Shudong Yang; You Zhou; Minhong Yu; Jiabei Liang; Ke Jin; Xing Huang; Peng Lu; Huan Cheng
Journal:  Med Oncol       Date:  2013-01-10       Impact factor: 3.064

8.  The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumor-suppressor protein promyelocytic leukemia protein.

Authors:  D Guan; D Factor; Yu Liu; Z Wang; H-Y Kao
Journal:  Oncogene       Date:  2012-09-03       Impact factor: 9.867

9.  Targeting microRNA/UHRF1 pathways as a novel strategy for cancer therapy.

Authors:  Hani Choudhry; Mazin A Zamzami; Ziad Omran; Wei Wu; Marc Mousli; Christian Bronner; Mahmoud Alhosin
Journal:  Oncol Lett       Date:  2017-10-30       Impact factor: 2.967

10.  UHRF1 regulation of the Keap1-Nrf2 pathway in pancreatic cancer contributes to oncogenesis.

Authors:  Wafa Abu-Alainin; Thompson Gana; Triantafillos Liloglou; Adedamola Olayanju; Lawrence N Barrera; Robert Ferguson; Fiona Campbell; Timothy Andrews; Christopher Goldring; Neil Kitteringham; Brian K Park; Taoufik Nedjadi; Michael C Schmid; Joseph R Slupsky; William Greenhalf; John P Neoptolemos; Eithne Costello
Journal:  J Pathol       Date:  2015-11-30       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.